Introduction
Acute coronary syndrome (ACS) is a leading cause of cardiovascular mortality and morbidity. Platelet indices have received increasing attention as possible markers of inflammation and of a greater risk for adverse cardiovascular outcomes. Although, easily detected platelet products with otomatic counter such as platelets count and mean platelet volume (MPV) are used in the prediction of major adverse cardiovascular events, the plateletcrit (PCT) has been investigated as a new predictor of cardiovascular risk. The plateletcrit (PCT) is part of the routine complete blood count and is an indicator of total platelet mass (PCT=platelet count × mean platelet volume [MPV]/107). Recent study reported an independent relation of high PCT values on admission with long-term adverse outcomes in ST-segment elevation myocardial infarction (STEMI) which underwent primary percutaneous coronary intervention.The aim of this study was to investigate the long-term prognostic significance of admission PCT values in patients with non-STEMI.
Methods
In this retrospective study, 296 patients (mean age 59.2±11.8 years; 228 male, 68 female), who were admitted to the emergency department with acute chest pain and taken a diagnosis of non-STEMI between February to December 2009, were enrolled. The study population was divided into tertiles based on admission PCT values. A high PCT (n=98) was defined as a value in the upper third tertile (PCT>0.23), and a low PCT (n=198) was defined as any value in the lower two tertiles (PCT≤0.23). The median follow-up time was 38 months for cardiovascular mortality, hospitalization for heartfailure, reinfarction, target vessel revascularization (TVR) and major adverse cardiovascular events (MACE). MACE was defined as the sum of risk of all study end-points.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
